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We have developed a methodology we call ROMA (representational oligonucleotide microarray analysis), for the
detection of the genomic aberrations in cancer and normal humans. By arraying oligonucleotide probes designed
from the human genome sequence, and hybridizing with “representations” from cancer and normal cells, we detect
regions of the genome with altered “copy number.” We achieve an average resolution of 30 kb throughout the
genome, and resolutions as high as a probe every 15 kb are practical. We illustrate the characteristics of probes on
the array and accuracy of measurements obtained using ROMA. Using this methodology, we identify variation
between cancer and normal genomes, as well as between normal human genomes. In cancer genomes, we readily
detect amplifications and large and small homozygous and hemizygous deletions. Between normal human genomes,
we frequently detect large (100 kb to 1 Mb) deletions or duplications. Many of these changes encompass known
genes. ROMA will assist in the discovery of genes and markers important in cancer, and the discovery of loci that
may be important in inherited predispositions to disease.
[The photoprint arrays were a kind gift of NimbleGen Systems Inc. and were fabricated to our design.]
Cancer is a disease caused, at least in part, by somatic and inher-
ited mutations in genes called oncogenes and tumor suppressor
genes. It is likely that we know only a minority of the critical
genes that are commonly mutated in the major cancer types. The
identification of these genes can lead to rational targets for che-
motherapy. Moreover, in many cases, the knowledge of which
genes have been mutated can predict the course of neoplasias,
including their therapeutic vulnerabilities, if any. This knowl-
edge is likely to become increasingly important as cancers, or
suspected cancers, are detected at earlier and earlier stages.
Methods for finding cancer genes date back to the early
1980s, but general methods have only recently been developed.
This problem is being addressed by a variety of evolving tech-
niques, some capable of detecting the genetic losses and ampli-
fications that often accompany the mutation of tumor suppres-
sor genes or oncogenes, respectively. We describe here our suc-
cess with ROMA (representational oligonucleotide microarray
analysis), a technique that evolved from an earlier method, RDA
(representational difference analysis; Lisitsyn et al. 1993). Like
RDA, ROMA detects differences present in cancer genomes.
ROMA also has applications to the identification of genetic varia-
tion in individuals caused by gene deletions or duplications,
some of which may be related to inherited disease.
We developed RDA as one general approach to the cancer
problem. RDA compares two genomes by subtractive hybridiza-
tion. To apply RDA, the complexity of the two genomes must
first be reduced so that hybridization can go nearly to comple-
tion. To achieve this, we use low-complexity representations, a
PCR-based method (Lisitsyn et al. 1993; Lucito et al. 1998). To
compare genomes, they are cleaved in parallel with a restriction
endonuclease, ligated to oligonucleotide adapters, and amplified
by PCR. The shorter restriction endonuclease fragments are pref-
erentially selected after many cycles of PCR, resulting in the re-
duced nucleotide complexity that is the essential characteristic of
representations.
RDA has been successfully used to detect deletions and am-
plifications in tumors, and its use has led to the discovery of
several candidate tumor suppressor genes and oncogenes (Li et al.
1997; Hamaguchi et al. 2002; Mu et al. 2003). However, RDA does
not lend itself to the high-throughput genomic profiling of hun-
dreds to thousands of cancer samples that can then be analyzed
in parallel. Such vast parallel analysis is likely to be needed if the
majority of complex genetic causes of cancer are to be identified.
Microarray analysis is a high-throughput method that has
been widely used to profile gene expression in cancers (DeRisi et
al. 1996; Golub et al. 1999; Van’t Veer et al. 2002), and three
groups, including ours, have adapted microarrays to detect ge-
nomic deletions and amplifications in tumors. Pinkel et al.
(1998) have used arrays of BAC DNAs as hybridization probes;
Pollack et al. (1999) have used cDNA fragments as probes; and in
our first implementation, we used microarrays of fragments from
representations as probes to analyze genomic representations
(Lucito et al. 2000). All three methods use the comparative “two-
color” scheme, in which simultaneous array hybridization de-
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tects a “normal” genome at one fluorescent wavelength and a
pathological genome at another.
We previously demonstrated that complexity reduction of
samples by representation improves signal-to-noise performance,
and diminishes the amount of sample required for analysis, rela-
tive to other microarray hybridization methods (Lucito et al.
2000). However, useful interpretation of genomic array hybrid-
ization data requires that the arrayed probes be mapped, and this
was a daunting task when we used fragments as probes. More-
over, in our previous implementation we used random fragment
libraries, and we therefore could not create arrays focused in cer-
tain regions of the genome at will.
Adopting microarrays of oligonucleotide probes solves these
problems. Representations are based on amplification of short
restriction endonuclease fragments, and hence are predictable
from the nucleotide sequence of the genome. Therefore, with
the publication of the rough draft of the human genome (Lander
et al. 2001), we can now design oligonucleotide probes that
will hybridize to representations, and map them computa-
tionally. We developed algorithms for choosing from each pre-
dicted short fragment a 70-mer (“long”) oligonucleotide probe
with a minimal degree of sequence overlap to the rest of the
genome. Through computation on the published human se-
quence, we can design almost any distribution of probes within
the genome.
There are many other advantages to oligonucleotide-based
microarrays. Based on our experience with the earlier implemen-
tation of this method using fragment arrays, the quality and
reproducibility of printed oligonucleotide arrays (“print format”)
are superior. Although there is a large initial capital outlay to
purchase large sets of oligonucleotides, the printed arrays are
very inexpensive per unit when costs are amortized, and labori-
ous and expensive replication of an underlying collection is not
required. Furthermore, “long” oligonucleotide probes can be syn-
thesized directly on an array surface (photoprinted arrays), and
we demonstrate herein the equivalence of the two formats. In the
photoprint format, there is no underlying physical collection at
all (Singh-Gasson et al. 1999). In either case, whether printed or
photoprinted, the composition of the array can be absolutely
specified and hence is completely reproducible by others.
We show results from two array formats. The printed arrays
are a format that is readily achievable. The regions that are rep-
resented on the array can be changed to suit the user. A whole-
genome array can be printed with the desired resolution. Smaller
ROMA arrays can be designed and printed to focus on specific
regions of the genome if wished, the advantage being that less
capital outlay would be required for a smaller set of oligonucleo-
tides. Results from the second format used, photoprint array,
were presented to demonstrate the power of high-resolution
copy number analysis.
In this paper, we demonstrate our system, illustrating results
and analytical techniques, present high-resolution analysis of
cancer genomes, and provide initial evidence for widespread
copy number polymorphism in humans. We discuss applications
of our method, compare our method to other methods for global
genomic analysis, and outline likely future developments.
RESULTS
Overview
This paper describes a complex procedure, observations, and
methods of analysis that are highly interactive. We therefore give
here an overview of our results to guide the reader through a
sensible reading of this portion of the manuscript. The first sec-
tion reviews the technique of representations, and in particular
“depleted” representations. Next we describe the design and se-
lection of probes selected to hybridize well to representations.
We introduce the two array formats that we use. The third sec-
tion illustrates how to use hybridization to depleted representa-
tions to validate the composition of an array design, and the
fourth section illustrates the use of such hybridization data to
characterize probes and model overall array performance. Next
we view essentially raw data of tumor and normal genomes, us-
ing two very different array formats, and show that the data from
both formats are highly comparable. In the next section, we dem-
onstrate a new statistical approach to gene copy number analysis
based on segmentation analysis, and apply the method to two
cancer genomes. The clonal nature of the cancers appears evi-
dent, as does the highly turbulent nature of their genomic rear-
rangements. The concordance between copy number analysis
and our mathematical model is re-examined. Then we look more
closely at several genetic lesions detected by our arrays following
our statistical processing. Several distinct types of lesions are il-
lustrated, including large regions of amplification and very nar-
row regions of homozygous and hemizygous deletion. Different
types of inferences that can be made by the method are demon-
strated. In the final section, we find a surprising abundance of
“normal” variation in copy number between two individuals,
and illustrate the need to coordinate data about such variation
with interpretation of cancer data.
Representations
Representations reduce the complexity of samples in a reproduc-
ible way, thereby increasing signal to noise during hybridization
to arrayed probes. Representations also provide a means to am-
plify the quantity of sample, and allow a very convenient way to
validate and simulate array performance.
In our present studies, we have limited ourselves to the use
of representations made with BglII, an enzyme with a typical 6-bp
recognition site. BglII is one of many restriction enzymes that
satisfy these useful criteria: It is a robust enzyme; its cleavage site
is not affected by CpG methylation; it leaves a four-base over-
hang; and its cleavage sites have a reasonably uniform distribu-
tion in the human genome. After cleavage with BglII, we ligate
adapters, and use the resulting product as a template for a PCR
reaction. Because PCR selects small fragments, BglII representa-
tions are made up of the short BglII fragments, generally smaller
than 1.2 kb, and we estimate that there are ∼200,000 of them,
comprising ∼2.5% of the human genome, with an average spac-
ing of 17 kb.
For array characterization, we use “depleted” BglII represen-
tations. These are representations made according to the usual
protocol, but prior to PCR (to selectively amplify small BglII frag-
ments), the adaptor-ligated BglII fragments are cleaved with a
second restriction endonuclease. Cleavage destroys the capacity
of some fragments to be exponentially amplified. For example, a
BglII representation-depleted by EcoRI would consist of all small
BglII fragments of the genome that do not contain within them
EcoRI sites. Depleted representations are used for probe valida-
tion and modeling performance because we can remove a known
subset of fragments from the representation, and observe the
consequence upon hybridization to those probes complementary
to the depleted fragments.
In all of the experiments described herein, we have used
comparative hybridization of representations prepared in paral-
lel. Our approach works best if the DNA from two samples being
compared is prepared at the same time, from the same concen-
tration of template, using the same protocols, reagents and ther-
mal-cycler. This diminishes the “noise” created by variable yield
upon PCR amplification.
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Design and Selection of Probes, and Composition of
Probes for Microarrays Formats
We describe the design (length and composition) and selection
of probes using two very distinct formats for the synthesis of
arrayed probes.
Our probes are derived from the short BglII restriction en-
donuclease fragments that we predict to exist from analysis of the
human genome sequence. We initially evaluated probes of
length 30 through 70, using methods described in the next sec-
tion. The signal-to-noise ratio was maximal for probes of 70 nt in
length, and we chose that length as our standard.
We selected our probes to be as unique as possible within
the human genome, and tried to minimize short homologies to
all unrelated sequences. We devised algorithms by which we
could annotate any sequence of the genome with its frequency of
exact matches in the genome (Healy et al. 2003). These algo-
rithms were used to choose regions within the predicted BglII
fragments that are unique for their constituent 18-mers or 21-
mers, and then within these regions, choose 70-mers with the
minimal arithmetic mean of their constituent 15-mer exact
matches. Subsets of the 70-mers were then tested for uniqueness
in the human genome by a low homology search using BLAST.
We used two formats for constructing microarrays. In the
first of these, the “print” format, we purchased nearly 10,000
oligonucleotides made with solid-phase chemistry, and printed
them with quills on a glass surface. In the second format, “pho-
toprint arrays,” oligonucleotides were synthesized directly on a
silica surface using laser-directed photochemistry by NimbleGen
Systems Inc. The photoprint arrays were a gift of NimbleGen
Systems Inc., and fabricated to our design. Manymore probes can
be synthesized per array with laser-directed photochemistry, and
in these experiments our arrays contained 85,000 oligonucleo-
tide probes.
The probe composition for the 85K set was determined by a
combination of design and selection, as described below. Unlike
oligonucleotide probes synthesized by standard phosphor-
amidite solid-phase chemistry, certain oligonucleotides synthe-
sized by laser-directed photochemistry are made in poor yield.
However, unlike probes synthesized by the solid-phase chemistry
and then printed, the cost of testing a set of probes synthesized
directly on a chip is no more than the cost of the chip itself.
Therefore, we tested ∼700,000 unique 70-nt probes (see Methods)
predicted to be complementary to small BglII fragments, arrayed
on eight chips. These were hybridized with standard BglII and
EcoRI-depleted BglII representations, and we picked the 85,000
with the most intense signal when hybridized to a single normal
human DNA, “J. Doe.” These 85,000 were then arrayed on a
single chip.
In both our 10K and 85K formats, probes are arrayed in a
random order, to minimize the possibility that a geometric arti-
fact during array hybridization will be incorrectly interpreted as
a genomic lesion.
Validation of Printed Arrays With
Depleted Representations
We should be able to observe a very clear and predictable pattern
to arrays hybridized with depleted representations if and only if
these conditions are met: The available human genome sequence
assembly is accurate; our method of probe design and selection is
valid; our hybridization conditions are sufficiently robust to give
a good signal-to-noise ratio for our probe population; and we
have correctly deconvoluted the probe addresses on our arrays
during data processing. We put all our array designs through
such tests. Moreover, the data we collect can further be used for
probe calibration and to create simulations that predict the
power of the array hybridization to detect various genomic le-
sions, as will be described in a following section.
To illustrate this process with a 10K array, we show in Figure
1 results obtained with BglII representations depleted by HindIII.
In Figure 1A, we graph the ratios of hybridization intensity of
each probe along the Y-axis. (See Methods for a description of
how we process raw scanned data. We perform no background
subtraction, as that only increases noise.) Each experiment is
performed in color reversal, and the geometric mean of ratios
from the separate experiments is plotted. Probes that we predict
to detect fragments in both the full and depleted representations,
based on the published human sequence, are grouped on the left.
There are ∼8000 probes that are predicted to be present in both
depleted and nondepleted representations. Probes that we pre-
dict will not detect fragments in the depleted representation are
grouped on the right. There are ∼1800 probes predicted as being
depleted.
From the experiment shown in Figure 1A, we can infer that
the promise of the method is largely fulfilled: The restriction
profile of representational fragments is correctly predicted, the
probes are correctly arrayed, and the probes detect the predicted
fragment with acceptable signal intensity.
To calculate the data shown in Figure 1A, each hybridization
was performed in color reversal, and the geometric mean of ratios
from the separate experiments was plotted. In Figure 1B, the
agreement between the ratios of the color reversal experiments is
graphed, as a log–log scatter plot, showing excellent correlation
of the data regardless of the labeling choice.
Modeling Array Hybridization
Variation in the ratio of intensities is evident from Figure 1A.
Some probes fail to exhibit the predicted elevated ratios. There
are several possible explanations for this. For example, the oligo-
nucleotide probe may not have been correctly or completely syn-
thesized, or the respective BglII fragment may not be present in
the representation as predicted. The latter can happen, for ex-
ample, if the public genome sequence is in error, or if there is a
polymorphism at one of the BglII sites in the sample genome
resulting in a longer BglII fragment than expected.
When, as here, there is significant variation in measure-
ments, statistical methods need to be used for the most accurate
interpretation of data. It is also often useful to construct a math-
ematical model that can simulate measurement. Moreover, a
good model can help predict the limits of detection, and be of
assistance in the design of experiments. In this section, we de-
scribe a mathematical model that fits the data, and in a later
section we describe statistical methods for data analysis. The
mathematical model is useful for individual probe characteriza-
tion, a clearer interpretation of the data, and the sharpening of
statistical tools.
There is always more than one way to model data, and vari-
ous enhancements can be added, but for our arrays we have
found that a simple equation and sampling technique creates a
model with great predictive power. This model will be described
in detail in a subsequent manuscript, but it is based on an equa-
tion for the intensity of the i-th probe in a given channel, I[i]:
I i =  *  * Ai * ci + .
In this equation, c[i] is the concentration of BglII fragment
complementary to the i-th probe prior to representation; and A[i]
is the combined “performance character” of the probe and its
complementary BglII fragment. The parameters of the equation
are elements of distributions.  is a multiplicative system noise; 
is an additive system noise that encompasses background hybrid-
ization; and  is the multiplicative noise created during parallel
Microarray Analysis of Gene Copy Number Variations
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representation and labeling. By definition, both  and  have a
mean of 1, and for a diploid genome, c[i] = 1.
A[i] can be viewed as the “brightness” of the i-th probe, and
is a major determinant of the signal-to-noise ratio. In principle,
A[i] should depend on at least two factors: the proportionate
amplification of the fragment complementary to the probe dur-
ing representation; and the purity of the probe. For example, a
probe that is complementary to a poorly amplified fragment will
have a low A value. Conversely, a probe complementary to a
well-amplified fragment should be “bright” and have a high sig-
nal-to-noise ratio. Similarly, a probe that is synthesized with poor
yield will have a low intensity and a poor signal-to-noise ratio.
Other factors may influence A, such as the secondary structure of
the probe and its base composition.
In the actual data, the highest ratios are observed from the
most intense probes (see Fig. 1C). According to the model, this is
explained by a fairly constant nonspecific signal for most probes.
That is,  is independent of the probe. Thus, the “brightest”
probes also have the highest specific to nonspecific signal. This
observation was the basis for our selection of the probes of the
85K set in the photoprint format (see above).
The model makes additional predictions: First, actual ratios
are linearly related to measured ratios, and second, the standard
deviation of probe measurement is a strong function of ratio,
being a minimum for ratios of unity. Using parameters derived
from the experiments displayed in Figure 1, we illustrate these
relationships in Figure 1D. We assume 15 sets of 600 probes with
various copy numbers n/4, with n = 0–14, bracketed by 600
probes of diploid copy number (4/4) on either end, measured
against a diploid genome (c[i] = 1), and measured in duplicate.
Note that the mean measured ratio of a set of probes is a linear
function of the “true” copy number, the number of gene copies
per cell, and the mean measured ratio, RM, of a subset of probes
reflects their true ratio, RT, by the following equation:
Figure 1 The predictability of informatics and accuracy of the array measurements using 10K microarrays. (A) The results, where the samples
hybridized are BglII representation and BglII representation depleted of fragments with a HindIII cleavage site. The Y-axis (Mean Ratio) is the mean
measured ratio from two hybridizations of depleted representation to normal representation plotted in log scale. The X-axis (Index) is a sorted index,
such that those probes that derive from fragments that do not have an internal HindIII restriction cleavage site sort first and those with an internal HindIII
site sort last. This allows the separation of these two subsets for visualization of the cleavage results. (B) The reproducibility of the duplicate experiments
used to generate the average ratio in A. The Y-axis (Ratio Exp1) is the measured ratio from experiment 1, and the X-axis (Ratio Exp2) is the measured
ratio of experiment 2. Both axes are plotted in log scale. (C) Graph of the normalized ratio on the Y-axis as a function of intensity of the sample that
was not depleted on the X-axis. Both the ratio and intensity were plotted in log scale. (D) Data generated by simulation. The X-axis (Index) is a false
index. Probes, in groups of 600, detect increasing copy number, from left to right; 600 flanking probes detect normal copy number. The Y-axis (Mean
Ratio) is the mean ratio calculated from two hybridizations.
Lucito et al.
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RM = RT * SN + 1SN + 1.
This is one general form of a linear equation in which RM = 1
when RT = 1. SN is an experimental character, which we think of
as “specific to nonspecific” noise. We can solve for SN from any
pair of nonunitary RM and RT values. We use this tool below to
analyze two cancer genomes, below.
Views of Tumor Genomes at 10K and 85K Resolution
Array hybridization data can be readily viewed, after deconvolu-
tion of probes into genomic order, without any model. In par-
ticular, genomic lesions, whether deletions or amplifications, are
visually obvious. We show in the matrix of panels of Figure 2 the
array hybridization data for three genomic comparisons. Figure
2, A1–A3, shows breast cancer (aneuploid) versus “normal” (dip-
loid) data from the same biopsy of a patient (CHTN159). Figure 2,
B1–B3, shows a breast cancer cell line (SK-BR-3) derived from a
patient of unknown ethnicity versus an unrelated normal male
(“J. Doe”) of mixed European and African parentage. Figure 2,
C1–C3, shows a normal male (African pygmy) versus the same J.
Doe. In each case, the samples were hybridized twice, with color
reversal, and the geometric mean ratio (on a log scale) is plotted
versus the genome order of the probes.
The samples from Figure 2A were derived by flow sorting the
nuclei of a surgical biopsy into aneuploid and diploid fractions,
and making representations from as few as 15,000 nuclei (∼100
ng of DNA). We estimate that the aneuploid fraction has perhaps
10% contamination from diploid nuclei, whereas the diploid
fraction is not expected to be completely normal. Nevertheless,
highly interpretable data result.
These data are in two formats: the 10K print format (Fig.
2A1,B1,C1) and an 85K photoprint format (Fig. 2A2,B2,C2). Un-
like the 10K format, probes of the 85K format were also selected
for performance, as described and justified in earlier sections.
This selection procedure produces a slight bias, in that no probe
from the 85K set will detect a small BglII fragment that is homo-
zygously missing in J. Doe. The consequences of this bias can be
seen in comparisons of the 10K print format with the 85K pho-
Figure 2 The genomic profiles for (A) a primary breast cancer sample (CHTN159), with aneuploid nuclei compared with diploid nuclei from the same
patient; (B) a breast cancer cell line compared with a normal male reference; and (C) a normal male compared with a normal male reference, using the
10K printed array (A1,B1,C1) and the 85K photoprint array (A2,B2,C2). In each case (rows 1 and 2), the Y-axis is the mean ratio, and the X-axis (Gen
Index) is an index of the probes’ genomic order based on the June 2002 assembly, that is, NCBI Build 30. The probes were put into genomic order
concatenating Chromosomes 1 through Y. (A3,B3,C3) The correspondence of the ratios measured from “brother” probes (see text for details) present
in the 10K and the 85K microarrays. The Y-axis is the measured ratio from the 10K microarray, and the X-axis is the measured ratio from the 85K
microarray.
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toprint format. In results from the 10K print format, there are
roughly equal numbers of extreme “singlets” above and below a
copy number of 1 (most apparent in Fig. 2C1). In contrast to this,
using the 85K format, more extreme singlets are below rather
than above a copy number of 1 (Fig. 2C2).
In Figure 2, A1, A2, B1, B2, C1, C2, increased copy number
is indicated by a ratio above 1, and decreased copy number by a
ratio below 1. Even at this global view, with all probes displayed,
several interesting observations can be made. There are clearly
profiles to the cancer genomes, large regions of amplification,
some quite high, and large regions of deletion (Fig. 2A,B). The
profiles of the cancer genomes are varied. In contrast, the profile
of the normal–normal appears to be flat, although some features
can be seen. These will be examined more closely below.
There are, in all three genomes, many stand-alone probes
detecting minor losses and gains, which we attribute to hetero-
zygous BglII polymorphism. These are manifest in the normal–
normal comparison (Fig. 2C2) as a “shell” of probes that ap-
proach ratios of 0.5 and 2.0 throughout the genome.
In contrast, in the tumor–normal comparison, wherein the
normal is matched, there is only one stand-alone probe detecting
major gains, and the stand-alone probes detecting major losses
are more or less confined to extensive regions showing minor
loss. This pattern is consistent with a hypothesis of allelic poly-
morphism and loss of heterozygosity (LOH). For a patient with
heterozygosity at a BglII fragment, with a large and a small frag-
ment, loss of the small allele will result in the virtual loss of
specific signal because the large allele will not be abundant in the
representation. This will present as an apparent major loss. On
the other hand, a loss of the large allele, for example, by gene
conversion, would at most result in a twofold increase in ratio,
appearing as a minor gain.
It is evident, looking at the results of the 10K print and the
85K photoprint formats in Figure 2, A1, A2, B1, B2, C1, C2, that
the two systems capture a similar view of the larger genomic
features. A correspondence between the two formats can be seen
quantitatively. We call probes “brothers” if they share comple-
mentarity to the same BglII fragment. Brothers do not necessarily
have overlapping sequence, or may be complementary across
their entire length. In Figure 2, A3, B3, C3, we plot the ratios of
brothers from one format to ratios of their brothers from the
other format. There are in excess of 7000 brother probes. For all
three experiments, in spite of the fact that the probe sequences
differ between formats, the order of arraying is different, the
hybridization conditions differ, and the surfaces of the array are
different, there is remarkable concordance between the ratios of
brother probes regardless of format.
Automated Segmentation and Whole-Genome Analysis
Because of the extent of the data, and its statistical nature, auto-
mated tools for feature recognition that are statistically based are
extremely useful. One part of our group has developed a statis-
tical segmentation algorithm termed circular binary segmenta-
tion (CBS) that parses the probe ratio data into segments of simi-
lar mean after taking variance into account (Olshen et al. 2002).
The algorithm works by analyzing one chromosome at a time
and, within that chromosome, recursively identifying the best
possible segmentation. Each proposed split is accepted or re-
jected based on the probability that the difference in mean could
have arisen by chance. This probability is determined using a
randomization method. The algorithm is a novel modification of
binary segmentation (Sen and Srivastava 1975). Because of its
nonparametric nature, the algorithm cannot identify aberrations
with fewer than three probes. We discuss detecting smaller le-
sions below.
Figure 3 illustrates some of the output for the analysis of the
cancer cell line SK-BR-3 at 85K resolution. We show four chro-
mosomes, the highly turbulent Chromosome 8, a somewhat
less active Chromosome 17, Chromosome 5, and the X-
chromosome. The segmentation profiles and segment means for
the 10K and 85K sets are very similar (data not shown), but
clearly are not identical. More features are seen with the 85K set.
In the next section, we inspect some of the data more closely. The
full data, and that for the other two genomes, can be viewed at
our Web site (http://roma.cshl.org/).
Once segmented, we can assign to every probe the mean
ratio of the segment to which it belongs, and then view the
assigned mean ratios in sorted order. We do this for the two
cancer genomes in Figure 4, A (CHTN159) and C (SK-BR-3). It is
evident from the figure the segment mean ratios within each
genome are quantized, with major and minor plateaus of similar
value. In fact, it is likely that we can deduce the copy number by
counting. As determined by flow analysis, the tumor is subtrip-
loid, and the cell line is tetraploid. Assuming each sample is
roughly monoclonal, then the two major plateaus in the tumor
would be two and three copies per cell, and the major plateaus in
the cell line are likely to be three and four copies per cell.
We can then use the copy number assumptions of the major
plateaus to solve the ploidy and SN for each experiment. Our
method is to use a version of equation 2 for each plateau. We
select RM, the mean measured ratio, as the average of the probes
of the segments in the plateau. We first set RT to CN/P, where CN
is the “true” copy number. CN is the number of gene copies per
cell, assumed to be known and equal for the plateau. P is the
ploidy of the tumor genome. The result is two equations and two
unknowns, with the unknowns being P and SN. For the tumor
biopsy experiment (Fig. 4A), we calculate the ploidy P to be 2.60,
and SN to be 1.13. For the cell line experiment (Fig. 4C), we
calculate that P is 3.93, and SN is 1.21. We can then use equation
2 again to calculate what mean ratios would be expected for
higher and lower copy numbers. These expectations are marked
on the respective graphs, from zero to a copy number of 12, with
horizontal lines forming a “copy number lattice.” The assigned
mean-segment values for probes are displayed in genome order,
embedded with the expected copy number lattice (Fig. 4B,D).
The copy number lattice fits remarkably well the minor pla-
teaus of the data, especially for the higher copy numbers. How-
ever, there appears to be error in the expected ratios for probes
detecting loss. The assigned mean-segment ratios of probes de-
tecting loss cluster around values somewhat below the predicted
values. In other words, the array appears to perform better for
deletions than predicted based on the major plateaus and our
present model. This deviation might be explained if we reexam-
ine our assumption of clonality, and will be investigated further.
Specific Illustrative Examples
There is clearly too much data to be described in a printed paper,
and the reader is invited to visit our Web page (http://
roma.cshl.org/). In this section, we discuss a few examples taken
from the array data of SK-BR-3 that illustrate several aspects of
our system.
The first example is a closer inspection of a region of a break
in the X-chromosome, seen in Figure 3D. SK-BR-3, which derives
from a female, has been compared to an unrelated male. The
expectation is that probes in the X-chromosome will have el-
evated ratios. This is the case through much of the long arm of
Chromosome X. In the midst of Xq13.3, over a region spanning
27 kb, there is a sharp break in copy number, and for the remain-
der of the chromosome, ratios near 1 are observed (Fig. 5A). This
example demonstrates the boundaries that can be drawn
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from the array data by segmentation. In our data there are other
examples of sharp copy number transitions that must break
genes.
There are three to four narrow amplifications in SK-BR-3,
each containing two or fewer genes, among which are transmem-
brane receptors. But broad amplifications can also be informa-
tive. The second example comes from the highly turbulent Chro-
mosome 8 (see Fig. 3B). Despite the abundance of aberrations, we
can clearly discern distinct regions of amplification. One such
region is shown in Figure 5B. The rightmost peak is approxi-
mately a 1-Mb stretch, comprised of 37 probes (probe coordinates
45099–45138, June 2002 assembly, or NCBI build 30 genome
coordinates 126815070–128207342). Yet it contains a single Ref-
Seq gene, c-myc.
There is a second very broad peak in SK-BR-3, ascending to
the left of the c-myc peak, and off the graph. This broad peak has
a broad shoulder on its right (probe coordinates 44994–45051,
June 2002 assembly, or NCBI build 30 genome coordinates
123976563–125564705), with a very narrow peak in its midst.
We can overlay on this the segmentation data from the tumor
genome, CHTN159, which has an even broader peak encompass-
ing c-myc (probe coordinates 44996–45131, June 2002 assembly,
or NCBI build 30 genomic coordinates 124073565–127828283).
The peak in CHTN159 also encompasses the shoulder of the sec-
ond SK-BR-3 peak (Fig. 5B). Thus, the shoulder may contain can-
didate oncogenes that merit attention. Within that region, at the
narrow peak, we find TRC8, the target of a translocation impli-
cated in hereditary renal carcinoma (Gemmill et al. 1998). This
example illustrates the value of coordinating data from multiple
genomes, and the need for automated methods for analyzing
multiple data sets.
We next show an example of a narrow deletion that high-
lights the need for high-resolution arrays, and also raises addi-
tional questions. The lesion occurs on Chromosome 5. In Figure
5C, we show a combined 10K (red) and 85K (blue) view. We do
not show segmentation, but show the copy number lattice. A
deletion is evident at both 10K and 85K resolutions (probe coor-
dinates 26496–26540, June 2002 assembly, or NCBI build 30 ge-
nomic coordinates 14231414–15591226), one we judge to be
hemizygous loss, but which may represent the presence of one
copy in a tetraploid genome. The boundaries are much more
clearly resolved at 85K. This region contains TRIO, a protein hav-
ing a GEF, SH3, and serine threonine kinase domain (Lin et al.
2000); ANKH, a transmembrane protein (Nurnberg et al. 2001);
Figure 3 Several chromosomes with varying copy number fluctuations from analysis of the tumor cell line SK-BR-3 as compared with the normal
reference. The Y-axis (Mean Ratio) represents the mean ratio of two hybridizations in log scale. The X-axis (Gen Index) is an index of the genomic
coordinates, as described above. (A) Copy number fluctuations identified for Chromosome 5, (B) for Chromosome 8, (C) for Chromosome 17, and (D)
for the X-chromosome.
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and FBXL, a component of the ubiquitin ligase mediated protein
degradation pathway (Ilyin et al. 2000).
It is also clear from the data that the lesion does not appear
“neat.” In the middle of the deletion are four or five probes that
report ratios near 1. We can consider several explanations for this
result. First, the hybridization to those probes may have failed for
a variety of reasons. For example, the probes might not have been
completely synthesized, or their complementary BglII fragments
might not have amplified well. However, the intensities of these
probes are in the middle range for all probe intensities, which
diminishes the likelihood of this hypothesis. Second, the human
assembly may be in error, and the outlier probes have been in-
correctly posted at this location. Third, the deletion event may
indeed be complex, the result of a localized genomic instability.
Our last example is a region of homozygous loss (Fig. 5D). In
this example, a cluster of zinc-finger proteins on Chromosome
19 is affected (probe coordinates 77142–77198, June 2002 assem-
bly, or NCBI build 30 genomic coordinates 21893948–
24955961). These genes, having zinc-finger domains, may en-
code transcription factors, whose deletion may have a role in
tumorigenesis.
There are an abundance of narrow hemizygous and homo-
zygous lesions. These are seen both in the analysis of the cancer
cell line and the cancer biopsy. However, as described below, we
must take caution in their interpretation. Our next examples will
all be in the context of normal–normal variation.
Examining Normal Genomic Variation
In this section, we demonstrate the need to coordinate cancer
genome analysis with a knowledge base of normal genomic
variation.
When the tumor DNA cannot be matched against normal
DNA, and an unrelated normal DNA is used as a reference, the
differences observed may be the result of polymorphic variation.
This variation can be of two sorts, the run-of-the-mill point se-
quence variation, of the sort that creates or destroys a BglII frag-
ment, SNPs for example, or actual copy number fluctuation pre-
sent in the human gene pool. The former is relatively harmless,
as it will produce scattered noise that can largely be filtered by
statistical means.
We illustrate the application of a very mild filtration algo-
rithm: If a ratio is the most deviant of the surrounding four, we
Figure 4 The mean segmentation calculated from the analysis of SK-BR-3 compared with (A,B) the normal reference and (C,D) CHTN159. In all panels,
the Y-axis is the value of the mean segment for each probe in log scale. In A and C, the X-axis (Mean Segment Index) is in ascending value of the assigned
mean segment. In B and D, the X-axis (Gen Index) is the genomic index, as described above. Plotted on top of the mean segment data is a copy number
lattice extrapolated from the array data using formulas within the text (horizontal lines). The calculated copy number for each horizontal line is to the
right of the lattice.
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replace it with the closer ratio of its two neighbors. In Figure 2C2,
we showed a normal–normal comparison. The data look flat,
with a cloud of scattered polymorphisms. In Figure 6A (com-
bined 10K and 85K sets), we have applied filtration. The data no
longer look so flat, and the cloud of scattered polymorphism is
lifted, revealing nonrandom clusters of deviant probe ratios.
These clusters reflect large-scale genomic differences between
normal individuals, and we will say more of this presently.
Polymorphic variation of the scattered variety can also be
filtered by serial comparison of experiments. We illustrate such a
process in Figure 6B. In this figure, we display data from SK-BR-3
compared with normal donor J. Doe, the 85K ratios displayed in
blue circles, and the 10K in red. On the same graph we display
the ratios of J. Doe compared with another normal, DNA from an
African pygmy, in green triangles. This is a fairly typical field of
view. We see three probes of extreme ratio in the SK-BR-3-normal
hybridization that can be identified as polymorphisms by com-
parison to hybridization between the two normal individuals.
The simplest interpretation is that J. Doe is +/+, pygmy +/, and
SK-BR-3 /, where + designates the presence of a small BglII
fragment and designates the absence of a fragment (most likely a
SNP at a BglII site). In general, pairwise comparisons of three
genomes allow interpretable calls of allele status. Hence, we sug-
gest that when a malignant genome cannot be paired to a
matched normal, or perhaps even when it can, such genomes
should be compared with a single reference normal donor, whose
allele status can be firmly established by extensive comparisons
against other normals.
Polymorphism in copy number, however, presents a differ-
ent sort of problem. In this case, many probes within a region
will show a deviation from a ratio of unity, and the pattern will
appear coherent, not scattered. Statistical means will not sup-
press this signal. But do such variations commonly exist, and are
they likely to be a source of misinterpretation if ignored? The
perhaps surprising answer is emphatically, yes.
Figure 6A indicates that there are gross regional differences
Figure 5 In all panels, the Y-axis (Mean Ratio SK-BR-3) is the mean ratio of two hybridizations of SK-BR-3 compared with a normal reference in log
scale. The X-axis (Gen Index) is the genomic index, as described. (A) A region from the X-chromosome with a region of loss. Plotted over the measured
array ratio is the calculated segmentation value. (B) A region of Chromosome 8 (c-myc located to the right of the center of the graph) from results of
SK-BR-3 in comparison to normal reference. Plotted on top of the data are the segmentation values for SK-BR-3 in comparison to the normal reference
in red and the segmentation values for the primary tumor CHTN159 in green. (C) A lesion on Chromosome 5 demonstrating the resolving power of
the 85K as compared with the 10K array. Results are from SK-BR-3 compared with a normal reference. Spots in red are from the 10K printed microarray,
and spots in blue are from the 85K photoprint array. Horizontal lines are copy number estimates, based on modeling from mean-segment values. (D)
Comparison of SK-BR-3 to normal reference, displaying a region of homozygous deletion on Chromosome 19. The mean-segment value is plotted as
a red line, and horizontal lines are copy number estimates as described.
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in the normal–normal comparison. Indeed, many regions that
display altered copy number between the two normal individuals
are revealed upon segmentation analysis. Close inspections of
two such regions are displayed in Figure 6, C and D, with ratios
as connected blue dots and copy number lattice values in orange.
In Figure 6C, the abnormal region is 135 kb on Chromosome
6p21 (probe coordinates 32518–32524, June 2002 assembly, or
NCBI build 30 genomic coordinates 35669083–35804705), and
encompasses three known genes. In Figure 6D, the region is a
620-kb region from Chromosome 2p11 (probe coordinates 9927–
9952, June 2002 assembly, or NCBI build 30 genomic coordinates
88787694–89385815) that contains a number of heavy chain
variable regions.
We observe on the order of a dozen such regions in any
normal–normal comparison. They range from 100 kb to >1Mb in
length and are more frequently observed near telomeres and cen-
tromeres, but can apparently occur anywhere. They often en-
compass known genes. We are presently investigating this phe-
nomenon more fully, and will report on them subsequently. For
now, we show how they impact the interpretation of cancer–
normal data.
In Figure 6, C and D, we have overlain the segmentation val-
ues from the analysis of SK-BR-3 in green. The copy number lattice
for SK-BR-3 is plotted as orange lines. Figure 6C illustrates a region
in SK-BR-3 that would be called a deletion in comparison to the
normal. In SK-BR-3 compared to normal, the flanking region occurs
at a copy number that we judge to be two copies per cell, andwithin
that region, copy number becomes reduced to one. But the same
region appears in the comparison of pygmy DNA to the same nor-
mal. In Figure 6D, we observe an analogous condition on Chromo-
some 2p11. In this panel, we have also plotted segmentation data
from the tumor. This region is evidently abnormal there as well.
Figure 6 (A) The results of a normal genomic profile compared with a normal, identical to that displayed in Figure 2C2 with the exception that singlet
probes have been filtered as described in the text. (B) The serial comparison of experiments for a small region from Chromosome 4. The Y-axis is the
mean ratio in log scale. The X-axis is the genomic index, as described. The blue (85K) and red (10K) spots are from the comparison of SK-BR-3 to normal.
The green is a comparison of a pygmy to the normal reference. (C) A lesion found in the normal population on Chromosome 6. The blue spots are
plotted by mean ratio for analysis of the pygmy to the normal reference. The red line is the mean-segment value for the pygmy-to-normal reference
comparison. The green line is the mean-segment value for the SK-BR-3-to-normal reference comparison. The blue line is the segment value from the
primary tumor (CHTN159 aneuploid to diploid) comparison. (D) A region of Chromosome 2. The data shown in blue circles are from the comparison
of SK-BR-3 to the normal reference. The mean-segment line for this comparison is shown in green. The mean-segment line for the comparison of a
pygmy to the normal reference is shown in red and for the primary tumor CHTN159 in blue. For C and D, the calculated copy number for the horizontal
lines is found to the right of the panel.
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Hence, we are inclined to view this “lesion” as pre-existing in the
normal cells of the patient.
DISCUSSION
Comparison of Methodologies for Global
Genomic Analysis
We have described a method, representational oligonucleotide
microarray analysis, or ROMA, that is useful for detecting ampli-
fications and deletions and sites of breakage in cancer and nor-
mal genomes. Detection of these events can in principle be used
to discover genes involved in cancer and other diseases of genetic
origin, and serve as markers or guides for the diagnosis and treat-
ment of such diseases. Because our method is sensitive to even
single nucleotide polymorphisms at restriction endonuclease
sites, it could in principle also be used as a high-density array for
detecting SNPs.
There are other methods for global analysis of cancers. Most
well known is the gene expression microarray (Chee et al. 1996;
DeRisi et al. 1996). This method does not find the primary lesions
in a cancer, but rather the sequels of mutation. Gene expression
microarrays are based on RNA extracted from tumors, and RNA is
a very unstable molecule, difficult to extract in a reliable manner.
Moreover, the outcome of expression array analysis will be ex-
tremely dependent on difficult-to-control factors such as sample
handling, and other complicating physiological variables such as
tumor infiltration by normal stroma and inflammatory cells. Our
method is based on DNA, a very stable molecule, easily extracted
even from tissue that has been mishandled. The DNA is the re-
pository of the causative molecular events, and the presence of
normal infiltrating stroma and inflammatory cells dilutes the
signal but does not change it. We do not intend for our method
to exclude RNA analysis, and in fact the two together would be
more valuable than either alone.
There are other DNA-based methods for measuring changes
in copy number in cancers. The oldest of these is fluorescent in
situ hybridization (FISH), which is used clinically to evaluate am-
plification at the ErbB-2 locus in breast cancer, for example (Tka-
chuk et al. 1990; Bartlett and Mallon 2003). In work in progress,
we have shown that our method is essentially equivalent for
evaluating amplification at ErbB-2, but, of course, our method
evaluates the entire genome, not just a single locus that may be
important in selecting cancer therapy. The major advantage of
FISH is that it is essentially a single-cell assay that can thus be
performed on very few cells, such as might be available upon
needle biopsy. Our method requires perhaps ∼2000 cells, and is a
mass measurement, not a single-cell assay. However, our method
points to loci that may be converted into FISH-based assays, and
that is a major strength.
Another DNA-based method is the BAC array, which is a
method that is more commonly known, and more widely prac-
ticed, than our method (Pinkel et al. 1998; Snijders et al. 2003).
Present BAC arrays suffer from much lower resolution, on the
order of 3000 probes. At their maximum, 30,000 member arrays,
there are still fewer probes into the genome, and the size of the
BAC, 150 to 200 kb, ultimately obscures high resolution. For
example, we can observe very small deletions and amplifications
that would be entirely missed with even high-density BAC arrays.
Additionally, because our method is based on representations,
our sample size can be smaller than is needed for the standard
BAC array protocol. (However, users of BAC arrays may use our
representational approaches to diminish their need for large
sample sizes.) Furthermore, BAC arrays cannot be fabricated to
industrial standards, as can our arrays. The composition of our
arrays is precisely specified, nucleotide for nucleotide, and a
highly reproducible standard product can be made available for
wide usage. Again, each and every one of our probes can be
readily calibrated for performance, a property that cannot be
readily done with BAC probes. Finally, our arrays are based on
oligonucleotides derived from the human sequence assembly,
the lingua franca of human genetics, and can therefore be pre-
cisely and automatically mapped into all the databases of all
mapped genes and genetic disorders. This cannot be done with
BACs, which can be unstable under propagation and can be chi-
meric. The one advantage of BAC arrays is that they are presently
cheaper, but that is likely to be a short-lived advantage.
cDNA arrays have also been used for measuring copy num-
ber mutations (Pollack et al. 1999; Hyman et al. 2002), whereby
whole genomic DNA is hybridized to a cDNA expression array.
These are presently insensitive. Moving averaging of the mea-
sured probe ratios is used to decrease system noise, and this re-
sults in a decrease in resolution. Therefore this methodology is
useful for the detection of larger amplifications and deletions.
However, detecting deletions is problematic because of overall
signal-to-noise issues of single fragment or oligonucleotide
probes. ROMA has overcome this problem by decreasing the
complexity of the genome, thereby increasing the signal-to-noise
ratio for each probe.
Is Our Knowledge of Cancer Complete?
Science has identified many of the commonly mutated genes in
cancer, and we know many of the cellular pathways on which
they act. Some think a basic theory of cancer is comprised of only
a few basic principles, sufficient to explain the nature of the
disease. However, it is a poor and unnecessary gamble to act as
though our theory is correct, or that our knowledge of specific
facts is nearly complete. Future progress in detection, prognosis,
and treatment of cancer will depend on the accuracy and com-
pleteness of our understanding of its specific molecular causes.
There are simple tests for the completeness of our under-
standing and knowledge of how cancers survive in and kill their
hosts. If our knowledge of the genes were complete, we would see
a plateau in the number of common mutant genes found in all
cancers. If our understanding of the principles were complete,
even advanced cancers with a large number of accumulated ge-
netic lesions would show only a small number of commonly
affected pathways. It follows from this, that if mutation in a
single gene were sufficient to affect a given pathway, even ad-
vanced cancers would show only a small number of commonly
affected genes, the remainder of lesions being highly sporadic.
The microarray-based method we have just described can
partially address these issues. We can readily identify loci in the
genome that undergo amplification, deletion, and imbalanced
breaks. Although there are many other possible mechanisms that
alter critical genes, such as point mutations, balanced transloca-
tions, and possibly stable epigenetic changes, many if not most
oncogenes and tumor suppressor genes will eventually be found
in the types of lesions that we can readily detect. Moreover, if a
region is commonly found altered in cancers, that region harbors
a good candidate cancer gene. Therefore, the application of our
method to a large series of cancers, and the comprehensive com-
parative analysis of such data, should reveal the existence and
number of candidate cancer genes in cancers.
Sources of Cancer Genomes
We have demonstrated the application of our method to two
types of sample: a tumor and a cancer cell line. There are advan-
tages and problems associated with each type. Cancer cell lines
are “universal” reagents. They are self-replenishing, and can be
passed between investigators. There is always ample material for
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analysis, and they tend to be monoclonal. They are suitable for
further functional analysis, whether by gene expression profil-
ing, genetic manipulation to restore or block a suspected tumor
suppressor gene or oncogene, or by tumorigenicity studies. Al-
most always there is no matched normal to control for scattered
polymorphic variation, but as we have described above, this is
not a serious limitation, as long as the unmatched normal can be
characterized. The significant disadvantages of cell lines are that
they can drift genetically, and they have undergone selection by
virtue of their survival in tissue culture. There is a limited reper-
toire of such cell lines, and no correlations between clinical pre-
sentation and copy number can be made.
The direct analysis of tumor material offers many opportu-
nities. There is a virtually unlimited source of different samples,
and they can often be matched to the same normal, easing some-
what the analytical burden of interpretation. It is in principle
possible to determine whether there are clinical parameters, such
as survival and drug responsiveness, that correlate with specific
gene amplification, deletions, and breakage, or overall patterns
of genomic instability. These correlations may find utility in the
treatment of patients. The disadvantages of tumor material are
also clear. Tumors are always contaminated with stroma, can be
oligoclonal, poorly preserved, and available in limiting amounts.
Fortunately, our method seems to be highly sensitive, and does
not require vast amounts of starting material. We routinely start
from 50 ng of sample, which corresponds to ∼10,000 nuclei, and
the method can be practiced with as few as 2000 nuclei or less.
Either flow sorting or microdissection can enrich tumor purity,
but amplifications and many deletions will be observable even
with material that is only 50% tumor (reconstruction experi-
ments; data not shown).
Technological Critique
Our method rests on three pillars: complexity reduction by rep-
resentations, the human genome assembly, and oligonucleotide
microarrays.
Because of the success of the human genome sequencing
project, and the reproducibility of representations, we are able to
design oligonucleotide probes that are complementary to a given
representation, such as the BglII representations that we have
used here. Because the human genome sequence is very reliable,
at least locally, we are able to experimentally validate our com-
putationally derived designs by exploiting the known restriction
endonuclease sites in our fragments (see Fig. 1). In principle, we
can thus calibrate every probe’s performance. The detection of
these ∼1800 predicted probes validates the ability of this method
to detect and identify copy number fluctuations. There are ∼10%
of the probes that are poor performers in the pin printed format.
By calibrating the probes, performance can be accounted for dur-
ing further analysis. Performance improves with the photo-
print format because of the empirical selection of the oligo-
nucleotides.
Of the 8000 probes predicted to hybridize to fragments not
cleaved by HindIII (see Fig. 1), ∼16 appear to hybridize to BglII
fragments that are in fact cleaved. We estimate that these 16
detect homozygous and heterozygous HindIII sites, in equal pro-
portion. We attribute this to a divergence of about one nucleo-
tide in 300 between our sample and the published human se-
quence, which could result from either polymorphism or se-
quencing errors. If this number were mainly caused by
polymorphism, then roughly one in 30 BglII fragments would
also be polymorphic. From other experiments, we estimate that
the rate of BglII polymorphism between unrelated individuals is
more on the order of one in 60, corresponding to a divergence
from the published human sequence of 1 in 600. Because the
public human sequence is reasonably well assembled, we auto-
matically have associated map positions for every probe that are
as accurate as the genome assembly. The algorithms we use for
designing these probes are in part described here, and in part in
Healy et al. (2003). Our approach allows us to design probes that
have minimal cross-reaction to the remainder of the genome.
Microarrays for any species, for example, mouse, can be built in
short order once a reliably complete and assembled genome se-
quence is publicly available.
There are many advantages to an oligonucleotide microar-
ray format. The composition of the microarray is precisely for-
mulated, and hence entirely reproducible by others. The work
presented here demonstrates the equivalence of measurements
achieved by the printed and light directed microarray formats.
Using printed arrays we can achieve densities of 30,000 probes
per slide, and using in situ light-directed synthesis, we have
achieved densities of 190,000, although only 85K data are illus-
trated here. The latter technique has many advantages over the
printed array. Besides achieving higher density, the layout of
probes and the choice of probes are flexible. Although the unit
cost of printed arrays is presently below the costs of light-directed
microarrays, with the latter there is no need for a large initial
capital expenditure for the purchase of oligonucleotides.
Our method is dependent on representations. Without com-
plexity reduction, which increases the concentration of DNA
complementary to the probes, signal intensity from specific hy-
bridization is too weak to measure above background. Depen-
dence on representations is a mixed blessing. Representations use
PCR both for the amplification of sample and complexity reduc-
tion. As a consequence, very little sample is required. However,
PCR does introduce noise, and this requires that the test sample
be compared with a control sample that is prepared exactly in
parallel. We find that if the starting DNAs of test and control are
of comparable quantity and quality, then subsequent parallel
sample preparation, from PCR to labeling, is usually sufficient to
give data of the type that is illustrated in this report.
There are a finite number of repeat-free 70-mer-long oligo-
nucleotide probes in the genome that are useful for measuring
BglII representations. We estimate that there are on the order of
120,000 of these scattered about the genome in a Poisson-like
distribution, and the distribution of probes does not reflect the
distribution of genes. At present we only array ∼85,000 probes.
Although the average distance between these 85,000 probes is
∼30 kb, there are regions of the genome that are very poorly
represented. We are therefore designing other types of represen-
tations, and other formats of probes, that will give us even higher
coverage of the genome. In principle, any desired density of cov-
erage is possible.
Data Interpretation
All array-based data require interpretation using statistical tools
of varying sophistication. Ours is no exception, but our system is
relatively unique. First, unlike cDNA expression profiling, there
are clear theoretical expectations of copy number measurements.
When comparing a test sample to a normal genome, there is a
clear expectation of how normals, except for polymorphisms,
will behave. Moreover, if the test sample is clonal, we expect
probe ratios to be clustered, reflecting discrete integral copy
numbers per cell. Second, because the restriction endonuclease
profile of fragments is known, virtually all probes can be cali-
brated, and array performance can be very accurately modeled.
Third, because the probes are ordered in the genome, and lesions
are expected to be regional, with defined starts and stops, the
expectation is that consecutive probe ratios within these regions
will share a distribution. Thus, we have developed “segmenta-
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tion” algorithms that are designed to parse the data into regions
with similar distributions.
Our present segmentation algorithm requires a minimum of
three probes to define a lesion, but clearly this is conservative.
For example, when our tumor sample is compared with a
matched normal, polymorphisms are controlled, and even a
single probe with an elevated copy number in the tumor is likely
to be meaningful. Other approaches to data analysis should be
pursued, and we are attempting to integrate polymorphism data,
probe calibration data, and probe intensity data into a more com-
prehensive model. Our present methods are not finished, but
they are clearly already useful. We expect that the borders of
regions can be drawn very sharply, most often to within a single
probe, and this is confirmed in modeling experiments (data not
shown).
We will report on our progress in statistical methods in sub-
sequent publications. In the end, however, no statistical inter-
pretation of a single experiment is certain, and only the accumu-
lation of larger data sets andmolecular confirmation can increase
confidence in a conclusion.
Normal Polymorphic Variation
Scattered polymorphism is evident in comparison of normal in-
dividuals, and even in the comparison of a single individual in a
“depletion” experiment (see Fig. 1). Most of these likely arise
from single nucleotide polymorphisms in the human popula-
tion. For example, loss of a BglII site may cause a fragment to be
absent in a BglII representation. Such events can interfere in data
interpretation in several ways. Except for the case of increased
copy number in a matched tumor–normal, the ratio from a single
probe outlier cannot be considered a somatic lesion, as it may
represent a genetic polymorphism, with or without loss of het-
erozygosity. Similarly, the boundaries of a segment may not be
accurately called if the bounding probe is complementary to a
polymorphic fragment. Lastly, a string of probes that by chance
are all complementary to polymorphic fragments may give rise to
the appearance of a consistent lesion. Fortunately, the frequency
of these polymorphisms is low, less than one fragment in 30, so
most boundaries are not obscured, and runs of polymorphisms
with the appearance of a lesion will occur rarely. Much of the
informatic “damage” caused by polymorphisms can be con-
tained, either by filtering out scattered outliers, or by accumulat-
ing data on normal genomes used for comparisons.
There is another type of “polymorphism” that we see, which
for now we call “copy number” polymorphism. This type is
much more interesting, and more pernicious, than scattered
polymorphism, and it is documented in Figure 6. A series of
regionally clustered probes may display a consistently altered ra-
tio in the comparison of one normal sample against another. We
see these regions in every normal–normal comparison that we
have made, and many of these lesions appear in cancer–normal
comparisons. In fact, some of these regions may be prone to
genomic instability (see Fig. 6D). They vary in size from <100 kb
to in excess of 1 Mb, and in most cases encompass genes. Creat-
ing a large database of normal–normal comparisons maymitigate
the misinterpretation of these lesions as somatic events occurring
in cancer, and this is something we intend to do.
Our present hypothesis is that these normal–normal varia-
tions are in fact copy number polymorphisms, genetic in origin,
but this is by no means proven here, nor is it the only plausible
hypothesis. For example, these variant regions might be caused
by locally high sequence divergence, or the consequence of
highly altered chromatin structure, affecting the yield of DNA
during purification from nuclei. Additional experimentation is
needed to resolve these questions, and work in progress strongly
indicates that the majority of these normal variations are, in-
deed, alterations in the gene pool. If there is, in fact, widespread
copy number variation in humans, such variation might well
contribute to human traits, including disease susceptibility and
resistance.
METHODS
Reagents
Oligonucleotides were synthesized by Illumina Inc. Human
Cot-1 DNA (15279-011) and yeast tRNA (15401-029) were sup-
plied by Invitrogen Inc. Restriction enzymes, ligase, and Klenow
fragments (M0212M ) were supplied by New England Biolabs.
The Megaprime labeling kit, Cy3-conjugated dCTP, and Cy5-
conjugated dCTP were supplied by Amersham-Pharmacia. Taq
polymerase was supplied by Eppendorf. Centricon YM-30 filters
were supplied by Amicon (42410), and formamide was supplied
by Amresco (0606-500). Phenol:chloroform was supplied by
Sigma (P2069). NimbleGen photoprint arrays were a gift from
NimbleGen Systems Inc.
Representation
BglII representations, in general, were prepared as previously de-
scribed (Lucito et al. 2003b). A major change is that amplification
was carried out in an MJ Research Tetrad. Sixteen 250-µL tubes
were used for amplification of the representation. The cycle con-
ditions were 95°C for 1 min, 72°C for 3 min, for 25 cycles, fol-
lowed by a 10-min extension at 72°C. The contents of the tubes
were pooled when completed. Representations were cleaned by
phenol:chloroform extraction, precipitated, resuspended, and
the concentration determined. Representations depleted of spe-
cific fragments by restriction enzyme were prepared in the same
manner with the following modification. After ligation of adap-
tor, the mixture was cleaned by phenol:chloroform extraction,
precipitated, and resuspended. The ligated fragments were then
digested with the second chosen enzyme. In the text, HindIII was
used. This material was then used as template in the PCR reac-
tion.
Probe Selection
We performed an in silico BglII digestion of the human genome
by locating all BglII restriction sites within the present draft as-
sembly and storing all sequences of BglII fragments that are be-
tween 200 and 1200 bp in length. Fragments were annotated
with the counts of their substituent, overlapping 15-mers and
21-mers using the “mer-engine” constructed from the same draft
assembly (see accompanying manuscript by Healy et al. 2003).
For each fragment, the following attributes were determined for
every substituent, overlapping 70-mer: maximum 21-mer count,
arithmetic mean of 15-mer counts, percent GC content, the
quantity of each base, and the longest run of any single base. All
70-mer probes that possess any of the following characteristics
were eliminated: maximum 21-mer count >1, GC content <30%
or >70%, a run of A/Ts >6 bases, a run of G/Cs >4 bases. From the
remaining set of 70-mers, the one (or more) that has a GC/AT
proportionality closest to that of the genome as a whole as well
as a minimal mean 15-mer count were selected. As a final check
for overall uniqueness, the optimal probes for each fragment
were compared with the entire genome using BLAST (default pa-
rameters were used with the exception of filtration of low com-
plexity sequence, which was not performed). Any probe found to
have any degree of homology along 50% or more of its length to
any sequence other than itself was eliminated.
Printed Arrays
We used the Cartesian PixSys 5500 (Genetic Microsystems) to
array our probe collection onto slides. We are presently using a
4 4 pin configuration. The dimension of each printed array
was roughly 2 cm2. Our arrays were printed on commercially
prepared silanated slides (Corning ultraGAPS #40015). Pins used
for the arrayer are from Majer Precision.
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Labeling
DNA was labeled as described (Lucito et al. 2003a). Briefly, place
DNA template (dissolved in TE at pH 8) in a 0.2-mL PCR tube.
Add 10 µL of Primers from the Amersham-Pharmacia Megaprime
labeling Kit and pipette up and down several times. Bring volume
up to 100 µL with dH2O, and mix. Place tubes in Tetrad at 100°C
for 5 min, then place on ice for 5 min and add 20 µL of labeling
buffer from the Amersham-Pharmacia Megaprime labeling Kit,
10 µL of label (Cy3-dCTP or Cy5-dCTP), and 1 µL of NEB Klenow
fragment. Place the tubes in a Tetrad and incubate at 37°C for 2
h. Combine the labeled samples (Cy3 and Cy5) into one Eppen-
dorf tube and add 50 µL of 1 µg/µL human Cot 1 DNA, 10 µL of
10 mg/mL stock yeast tRNA, and 80 µL of Low TE (3 mM Tris at
pH 7.4, 0.2 mM EDTA). Load all into a Centricon Filter and cen-
trifuge for 10 min at 12,600 rcf. Discard flowthrough and wash
with 450 µL of Low TE. Centrifuge at 12,600 rcf and repeat twice.
Collect the labeled sample by inverting the centricon column
into a new tube and centrifuging for 2 units at 12,600 rcf. Trans-
fer labeled sample to a 200-µL PCR tube and adjust volume to 10
µL of Low TE.
Slide Preparation
Slides were prepared as in Lucito et al. (2003a) with the following
changes. Prehybridization buffer for printed microarrays con-
sisted of the following, 25% deionized formamide, 5 SSC, and
0.1% SDS. Pour into a coplin jar or other slide processing cham-
ber and preheat to 61°C. UV cross-link DNA to slide (using a
Strategene Statalinker, set Energy to 300 mJ, rotate slide 180°,
keeping the slide in the same spot in the cross-linker, and repeat).
NimbleGen photoprinted arrays do not require UV cross-linking.
Wash slides in the following solutions: 2 min in 0.1% SDS, 2 min
in milliQ H2O, 5 min in milliQ H2O that has boiled, and finally
in ice cold 95% benzene-free EtOH. Dry slides by placing in a
metal rack and spin at 75 rcf for 5 min. Printed microarray slides
were incubated in the 61°C prehyb solution. After 2 h, wash
slides in milliQ H2O for 10 sec. Dry slides by placing in a metal
slide rack and spin for 5 min at 75 rcf. NimbleGen photoprinted
arrays do not require prehybridization.
Hybridization
The hybridization solution for printed slides consisted of 25%
formamide, 5 SSC, and 0.1% SDS. The hybridization solution
for NimbleGen photoprinted arrays consisted of 50% formamide,
5 SSC, and 0.1%SDS. For each, 25 µL of hybridization solution
was added to the 10 µL of labeled sample and mixed. Samples
were denatured in an MJ Research Tetrad at 95°C for 5 min, and
then incubated at 37°C for 30 min. Samples were spun down and
pipetted onto a slide prepared with lifter slip and incubated in a
hybridization oven such as the Boekel InSlide Out oven set at
58°C for printed arrays or 42°C for NimbleGen photoprinted ar-
rays for 14 to 16 h. After hybridization, slides were washed as
follows: brief wash in 0.2% SDS/0.2 SSC to remove the cover-
slip, 1 min in 0.2% SDS/0.2 SSC, 30 sec in 0.2 SSC, and 30 sec
in 0.05 SSC. Slides were dried as before by placing in a rack and
spinning at 75 rcf for 5 min, and then scanned immediately. An
Axon GenePix 4000B scanner was used setting the pixel size to 10
µm for printed arrays and 5 µm for NimbleGen photoprinted
arrays. GenePix Pro 4.0 software was used for quantitation of
intensity for the arrays. Array data were imported into S-PLUS for
further analysis. Measured intensities without background sub-
traction were used to calculate ratios. Data were normalized using
an intensity-based lowest curve fitting algorithm similar to that
described in Yang et al. (2002). Data obtained from color reversal
experiments were averaged and displayed as presented in the
figures.
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